Functional Outcome, Recanalization, and Hemorrhage Rates After Large Vessel Occlusion Stroke Treated With Tenecteplase Before Thrombectomy.
Aged
Aged, 80 and over
Brain Ischemia
/ complications
Cerebral Hemorrhage
/ complications
Female
Fibrinolytic Agents
Humans
Ischemic Stroke
Male
Middle Aged
Retrospective Studies
Stroke
/ complications
Tenecteplase
/ therapeutic use
Thrombectomy
/ methods
Thrombolytic Therapy
/ methods
Treatment Outcome
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
30 11 2021
30 11 2021
Historique:
received:
09
03
2021
accepted:
21
09
2021
pubmed:
13
10
2021
medline:
7
4
2022
entrez:
12
10
2021
Statut:
ppublish
Résumé
To investigate in routine care the efficacy and safety of IV thrombolysis (IVT) with tenecteplase prior to mechanical thrombectomy (MT) in patients with large vessel occlusion acute ischemic strokes (LVO-AIS), either secondarily transferred after IVT or directly admitted to a comprehensive stroke center (CSC). We retrospectively analyzed clinical and procedural data of patients treated with 0.25 mg/kg tenecteplase within 270 minutes of LVO-AIS who underwent brain angiography. The main outcome was 3-month functional independence (modified Rankin Scale score ≤2). Recanalization (revised Treatment in Cerebral Ischemia score 2b-3) was evaluated before (pre-MT) and after MT (final). We included 588 patients (median age 75 years [interquartile range (IQR) 61-84]; 315 women [54%]; median NIH Stroke Scale score 16 [IQR 10-20]), of whom 520 (88%) were secondarily transferred after IVT. Functional independence occurred in 47% (n = 269/570; 95% confidence interval [CI] 43.0-51.4) of patients. Pre-MT recanalization occurred in 120 patients (20.4%; 95% CI 17.2-23.9), at a similar rate across treatment paradigms (direct admission, n = 14/68 [20.6%]; secondary transfer, n = 106/520 [20.4%]; Tenecteplase before MT is safe, effective, and achieves a fast recanalization in everyday practice in patients secondarily transferred or directly admitted to a CSC, in line with published results. These findings should encourage its wider use in bridging therapy. This study provides Class IV evidence that tenecteplase within 270 minutes of LVO-AIS increases the probability of functional independence.
Sections du résumé
BACKGROUND AND OBJECTIVES
To investigate in routine care the efficacy and safety of IV thrombolysis (IVT) with tenecteplase prior to mechanical thrombectomy (MT) in patients with large vessel occlusion acute ischemic strokes (LVO-AIS), either secondarily transferred after IVT or directly admitted to a comprehensive stroke center (CSC).
METHODS
We retrospectively analyzed clinical and procedural data of patients treated with 0.25 mg/kg tenecteplase within 270 minutes of LVO-AIS who underwent brain angiography. The main outcome was 3-month functional independence (modified Rankin Scale score ≤2). Recanalization (revised Treatment in Cerebral Ischemia score 2b-3) was evaluated before (pre-MT) and after MT (final).
RESULTS
We included 588 patients (median age 75 years [interquartile range (IQR) 61-84]; 315 women [54%]; median NIH Stroke Scale score 16 [IQR 10-20]), of whom 520 (88%) were secondarily transferred after IVT. Functional independence occurred in 47% (n = 269/570; 95% confidence interval [CI] 43.0-51.4) of patients. Pre-MT recanalization occurred in 120 patients (20.4%; 95% CI 17.2-23.9), at a similar rate across treatment paradigms (direct admission, n = 14/68 [20.6%]; secondary transfer, n = 106/520 [20.4%];
DISCUSSIONS
Tenecteplase before MT is safe, effective, and achieves a fast recanalization in everyday practice in patients secondarily transferred or directly admitted to a CSC, in line with published results. These findings should encourage its wider use in bridging therapy.
CLASSIFICATION OF EVIDENCE
This study provides Class IV evidence that tenecteplase within 270 minutes of LVO-AIS increases the probability of functional independence.
Identifiants
pubmed: 34635558
pii: WNL.0000000000012915
doi: 10.1212/WNL.0000000000012915
doi:
Substances chimiques
Fibrinolytic Agents
0
Tenecteplase
WGD229O42W
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2173-e2184Investigateurs
Vincent Degos
(V)
Mariana Sarov
(M)
Nicolas Legris
(N)
Olivier Chassin
(O)
Djibril Soumah
(D)
Tony Altarcha
(T)
Carole Imbernon
(C)
Pauline Renou
(P)
Mathilde Poli
(M)
Sabrina Debruxelles
(S)
Sharmila Sagnier
(S)
François Rouanet
(F)
Jean-Sebastien Liegey
(JS)
David Calvet
(D)
Jean-Claude Baron
(JC)
Laure Bottin
(L)
Stephen Delorme
(S)
Jean Capron
(J)
Diana Doukhi
(D)
Sam Ghazanfari
(S)
David Weisenburger
(D)
Edwige Lescieux
(E)
Florent Gariel
(F)
Xavier Barreau
(X)
Patrice Menegon
(P)
Thomas Tourdias
(T)
Catherine Oppenheim
(C)
Olivier Naggara
(O)
Titien Tuilier
(T)
Nader Sourour
(N)
Nader Sourour
(N)
Eimad Shotar
(E)
Stéphanie Lenck
(S)
Kévin Premat
(K)
Raphaël Blanc
(R)
Simon Escalard
(S)
Robert Fahed
(R)
Stanislas Smajda
(S)
Mikael Mazighi
(M)
Informations de copyright
© 2021 American Academy of Neurology.